Increasing incidence rate of breast cancer in cystic fibrosis - relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens
Language English Country England, Great Britain Media electronic
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
36941680
PubMed Central
PMC10029289
DOI
10.1186/s13023-023-02671-z
PII: 10.1186/s13023-023-02671-z
Knihovny.cz E-resources
- Keywords
- Anticancer treatment, Breast cancer, CFTR modulator therapy, Cystic fibrosis, Estrogens,
- MeSH
- Cystic Fibrosis * drug therapy genetics MeSH
- Estrogens therapeutic use MeSH
- Incidence MeSH
- Carcinogenesis MeSH
- Humans MeSH
- Mutation MeSH
- Breast Neoplasms * drug therapy complications MeSH
- Gonadal Steroid Hormones therapeutic use MeSH
- Prognosis MeSH
- Cystic Fibrosis Transmembrane Conductance Regulator genetics MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Estrogens MeSH
- Gonadal Steroid Hormones MeSH
- Cystic Fibrosis Transmembrane Conductance Regulator MeSH
Cystic fibrosis (CF) is the most common genetic disease in the Caucasion population. Thanks to the CFTR modulators therapy, life expectancy will significantly improve. New therapeutic challenges can be expected, including diseases associated with ageing and higher incidence of cancer, as evidenced by recent epidemiological studies. The increasing incidence of tumors includes also breast cancer. The risk of breast cancer is higher in CF patients compared to the general population. Sex hormones, especially estrogens, also affect on the pathophysiology and immunology of the CF. Previous research, has demonstrated unequivocal survival rates for female CF patients compared to their male counterparts. Is demonstrated, that chemotherapy used for breast cancer affects the CFTR channel and CFTR modulator therapy has frequent side effects on breast tissue. In this review, we focus on the effects of female sex hormones on CF disease, pathophysiological relationships between CF and breast cancer, and the impact of antitumor treatment on both, malignant disease and CF. The potential for further investigation is also discussed.
Department of Pulmonary Medicine Oslo University Hospital Kirkeveien 166 Ullevål Oslo 0450 Norway
Department of Respiratory Diseases University Hospital Brno Jihlavska 20 Brno 62500 Czech Republic
Faculty of Medicine Masaryk University Brno Kamenice 5 Brno 62500 Czech Republic
See more in PubMed
ECFSPR Report. 2019. [cited 2022 14th July]. Available from: https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2019_v1_16Feb2022.pdf.
Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry 2017 Annual Data Report. [cited 2022 14th July]. Available from: www.cysticfibrosis.ca/blog/2017-registry-annual-data-report/.
Archangelidi O, Cullinan P, Simmonds NJ, Mentzakis E, Peckham D, Bilton D, et al. Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. J Cyst Fibros. 2022;21(2):302–8. doi: 10.1016/j.jcf.2021.07.004. PubMed DOI
Alicandro G, Bisogno A, Rota M, Padoan R, Colombo C. No gender differences in growth patterns in a cohort of children with cystic fibrosis born between 1986 and 1995. Clin Nutr. 2019;38(4):1782–7. doi: 10.1016/j.clnu.2018.07.025. PubMed DOI
Schram CA, Stephenson AL, Hannam TG, Tullis E. Cystic fibrosis (CF) and ovarian reserve: a cross-sectional study examining serum anti-mullerian hormone (AMH) in young women. J Cyst Fibros. 2015;14(3):398–402. doi: 10.1016/j.jcf.2014.09.008. PubMed DOI
Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res. 2021;7(1):000475–2020. doi: 10.1183/23120541.00475-2020. PubMed DOI PMC
Garcia FU, Galindo LM, Holsclaw DS. Breast abnormalities in patients with cystic fibrosis: previously unrecognized changes. Ann Diagn Pathol. 1998;2(5):281–5. doi: 10.1016/S1092-9134(98)80019-1. PubMed DOI
Neglia JP, Fitzsimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M, et al. The risk of Cancer among patients with cystic fibrosis. N Engl J Med. 1995;332(8):494–9. doi: 10.1056/NEJM199502233320803. PubMed DOI
Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-Year Nationwide Study from the United States. JNCI: J Natl Cancer Inst. 2013;105(2):122–9. doi: 10.1093/jnci/djs481. PubMed DOI
Johannesson M, Askling J, Montgomery SM, Ekbom A, Bahmanyar S. Cancer risk among patients with cystic fibrosis and their first-degree relatives. Int J Cancer. 2009;125(12):2953–6. doi: 10.1002/ijc.24679. PubMed DOI
Appelt D, Fuchs T, Steinkamp G, Ellemunter H. Malignancies in patients with cystic fibrosis: a case series. J Med Case Rep. 2022;16(1):27. doi: 10.1186/s13256-021-03234-1. PubMed DOI PMC
Shi Z, Wei J, Na R, Resurreccion WK, Zheng SL, Hulick PJ, et al. Cystic fibrosis F508del carriers and cancer risk: results from the UK Biobank. Int J Cancer. 2021;148(7):1658–64. doi: 10.1002/ijc.33431. PubMed DOI
Southey MC, Batten L, Andersen CR, McCredie MR, Giles GG, Dite G, et al. CFTR delF508 carriers status, risk of breast cancer before the age of 40 and histological grading in a population-based case-control study. Int J Cancer. 1998;79:487–9. doi: 10.1002/(SICI)1097-0215(19981023)79:5<487::AID-IJC7>3.0.CO;2-X. PubMed DOI
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: CA Cancer J Clin 2021;71(3):209 – 49. PubMed
Saha T, Makar S, Swetha R, Gutti G, Singh SK. Estrogen signaling: an emanating therapeutic target for breast cancer treatment. Eur J Med Chem. 2019;177:116–43. doi: 10.1016/j.ejmech.2019.05.023. PubMed DOI
Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor necrosis factor α blockade: an opportunity to tackle breast Cancer. Front Oncol. 2020;10:584. doi: 10.3389/fonc.2020.00584. PubMed DOI PMC
Chen GG, Zeng Q, Tse GMK. Estrogen and its receptors in cancer. Med Res Rev. 2008;28(6):954–74. doi: 10.1002/med.20131. PubMed DOI
Hughan KS, Daley T, Rayas MS, Kelly A, Roe A. Female reproductive health in cystic fibrosis. J Cyst Fibros. 2019;18:95–S104. doi: 10.1016/j.jcf.2019.08.024. PubMed DOI
Chotirmall SH, Greene CM, Oglesby IK, Thomas W, O’Neill SJ, Harvey BJ, et al. 17β-Estradiol inhibits IL-8 in cystic fibrosis by Up-Regulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med. 2010;182(1):62–72. doi: 10.1164/rccm.201001-0053OC. PubMed DOI
Zhang JT, Jiang XH, Xie C, Cheng H, Da Dong J, Wang Y, et al. Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta Mole Cell Res. 2013;1833(12):2961–9. doi: 10.1016/j.bbamcr.2013.07.021. PubMed DOI
Song Y, Wang Q, Huang W, Xiao L, Shen L, Xu W. NF kappaB expression increases and CFTR and MUC1 expression decreases in the endometrium of infertile patients with hydrosalpinx: a comparative study. Reprod Biol Endocrinol. 2012;10(1):86. doi: 10.1186/1477-7827-10-86. PubMed DOI PMC
Rochwerger L, Buchwald M. Stimulation of the cystic fibrosis transmembrane regulator expression by estrogen in vivo. Endocrinology. 1993;133(2):921–30. doi: 10.1210/endo.133.2.7688293. PubMed DOI
Ajonuma LC, Tsang LL, Zhang GH, Wong CHY, Lau MC, Ho LS, et al. Estrogen-Induced abnormally high cystic fibrosis transmembrane Conductance Regulator expression results in ovarian hyperstimulation syndrome. Mol Endocrinol. 2005;19(12):3038–44. doi: 10.1210/me.2005-0114. PubMed DOI
Prulière-Escabasse V, Fanen P, Dazy AC, Lechapt-Zalcman E, Rideau D, Edelman A, et al. TGF-β1 downregulates CFTR expression and function in nasal polyps of non-CF patients. Am J Physiol Lung Cell Mol Physiol. 2005;288(1):L77–L83. doi: 10.1152/ajplung.00048.2004. PubMed DOI
Abraham EH, Vos P, Kahn J, Grubman SA, Jefferson DM, Ding I, et al. Cystic fibrosis hetero–and homozygosity is associated with inhibition of breast cancer growth. Nat Med. 1996;2(5):593–6. doi: 10.1038/nm0596-593. PubMed DOI
Vertex Pharmaceuticals Inc., Kaftrio (ivacaftor/tezacaftor/elexacaftor) full prescribing information. 2020
Jeyaratnam J, van der Meer R, Berkers G, Heijerman HGM, Beekman JM, van der Ent CK. Breast development in a 7 year old girl with CF treated with ivacaftor: an indication for personalized dosing? J Cyst Fibros. 2021;20(5):e63–6. doi: 10.1016/j.jcf.2021.06.001. PubMed DOI
Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003;9(2):827–36. PubMed
Imberti R, Garavaglia ML, Verduci I, Cannavale G, Balduzzi G, Papetti S, et al. Antiestrogen- and tamoxifen-induced effects on calcium-activated chloride currents in epithelial cells carrying the ∆ F508-CFTR point mutation. Respir Res. 2018;19(1):198. doi: 10.1186/s12931-018-0901-1. PubMed DOI PMC
Nobuzane T, Tashiro S, Kudo Y. Morphologic effects of epithelial ion channels on the mouse uterus: differences between raloxifene analog (LY117018) and estradiol treatments. Am J Obstet Gynecol 2008;199(4):363.e1-363.e6. PubMed
Maitra R, Hamilton J. Altered Biogenesis of ∆F508-CFTR following treatment with Doxorubicin. Cell Physiol Biochem. 2007;20(5):465–72. doi: 10.1159/000107530. PubMed DOI
Lallemand JY, Stoven V, Annereau JP, Boucher J, Blanquet S, Barthe J, et al. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet. 1997;350(9079):711–2. doi: 10.1016/S0140-6736(05)63510-6. PubMed DOI
Ruffles TJC, Black R, Nicholls W, Laing B, Isles A. Osteogenic sarcoma in an adolescent with cystic fibrosis: successful treatment despite significant obstacles. Front Pediatr. 2018;6:345. doi: 10.3389/fped.2018.00245. PubMed DOI PMC
Ballmann M, Junge S, Von Der Hardt H. Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis. Respir Med. 2003;97(5):498–500. doi: 10.1053/rmed.2002.1471. PubMed DOI
